BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15120365)

  • 1. Role of retinoid X receptor mRNA expression in Barrett's esophagus.
    Brabender J; Lord RV; Metzger R; Park J; Salonga D; Danenberg KD; Hölscher AH; Danenberg PV; Schneider PM
    J Gastrointest Surg; 2004; 8(4):413-22. PubMed ID: 15120365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence.
    Lord RV; Tsai PI; Danenberg KD; Peters JH; Demeester TR; Tsao-Wei DD; Groshen S; Salonga D; Park JM; Crookes PF; Kiyabu M; Chandrasoma P; Danenberg PV
    Surgery; 2001 Mar; 129(3):267-76. PubMed ID: 11231454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Park JM; Salonga D; Groshen S; Tsao-Wei DD; DeMeester TR; Hölscher AH; Danenberg PV
    J Surg Res; 2001 Aug; 99(2):301-6. PubMed ID: 11469901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Brabender J; Lord RV; Danenberg KD; Metzger R; Schneider PM; Uetake H; Kawakami K; Park JM; Salonga D; Peters JH; DeMeester TR; Hölscher AH; Danenberg PV
    J Gastrointest Surg; 2001; 5(2):174-81; discussion 182. PubMed ID: 11331481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence.
    Lord RV; Salonga D; Danenberg KD; Peters JH; DeMeester TR; Park JM; Johansson J; Skinner KA; Chandrasoma P; DeMeester SR; Bremner CG; Tsai PI; Danenberg PV
    J Gastrointest Surg; 2000; 4(2):135-42. PubMed ID: 10675236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.
    Brabender J; Lord RV; Wickramasinghe K; Metzger R; Schneider PM; Park JM; Hölscher AH; DeMeester TR; Danenberg KD; Danenberg PV
    J Gastrointest Surg; 2002; 6(3):359-67. PubMed ID: 12022988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential SPARC mRNA expression in Barrett's oesophagus.
    Brabender J; Lord RV; Metzger R; Park J; Salonga D; Danenberg KD; Danenberg PV; Hölscher AH; Schneider PM
    Br J Cancer; 2003 Oct; 89(8):1508-12. PubMed ID: 14562024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
    Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
    Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma.
    Bobryshev YV; Freeman AK; Botelho NK; Tran D; Levert-Mignon AJ; Lord RV
    Dis Esophagus; 2010 Sep; 23(7):580-9. PubMed ID: 20459440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus.
    Brabender J; Marjoram P; Salonga D; Metzger R; Schneider PM; Park JM; Schneider S; Hölscher AH; Yin J; Meltzer SJ; Danenberg KD; Danenberg PV; Lord RV
    Oncogene; 2004 Jun; 23(27):4780-8. PubMed ID: 15107828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
    O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
    Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barrett's esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reflux.
    Sarr MG; Hamilton SR; Marrone GC; Cameron JL
    Am J Surg; 1985 Jan; 149(1):187-93. PubMed ID: 3966636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.
    O'Farrell NJ; Feighery R; Picardo SL; Lynam-Lennon N; Biniecka M; McGarrigle SA; Phelan JJ; MacCarthy F; O'Toole D; Fox EJ; Ravi N; Reynolds JV; O'Sullivan J
    BMC Cancer; 2016 Jul; 16():497. PubMed ID: 27431913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis.
    Jankowski J; Hopwood D; Pringle R; Wormsley KG
    Am J Gastroenterol; 1993 Mar; 88(3):402-8. PubMed ID: 8438848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.